[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359771-105":59,"doc-detail-359771-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","innovative-biomaterial-solutions-for-enhancing-the-efficacy-of-tumor-immunotherapy","Innovative biomaterial solutions for enhancing the efficacy of tumor immunotherapy","","Cancer persists as a major global health burden, intensified by demographic growth and population aging. Tumor immunotherapy leverages immune responses to eliminate cancers, yet still suffers from inadequate immune activation, suboptimal targeting, and treatment-related side effects. Biomaterial innovations—including liposomes, nanoparticles, micelles, and hydrogels—can strengthen delivery of immunotherapeutic agents, improve pharmacokinetics, enable controlled release, enhance immune-cell interactions, and mitigate off-target toxicity. This review synthesizes present technologies, mechanisms, and future directions toward more precise, personalized cancer treatment outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/innovative-biomaterial-solutions-for-enhancing-the-efficacy-of-tumor-immunotherapy/359771/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/innovative-biomaterial-solutions-for-enhancing-the-efficacy-of-tumor-immunotherapy/359771.png","ImageObject",300,407,{"name":92,"@type":93},"Taylor Morgan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What limitations currently hinder effective tumor immunotherapy?","Question",{"text":112,"@type":113},"Key challenges include inadequate immune activation, poor targeting, inefficient delivery, limited precision, and unintended adverse effects in some patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do biomaterials improve immunotherapy outcomes?",{"text":117,"@type":113},"Engineered biomaterials enhance delivery and efficacy of immunotherapeutic agents, improve pharmacokinetics, enable controlled release, facilitate immune-cell interactions, and reduce off-target toxicity.",{"name":119,"@type":110,"acceptedAnswer":120},"Which cytokines are highlighted as early agents for cancer immunotherapy?",{"text":121,"@type":113},"The review points to interleukin-2 (IL-2) and interferon-alpha (IFN-α), both approved by the FDA for various cancer treatments, with noted limitations related to side effects or effectiveness.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},359771,1790379153,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Immunologic Research (2026) 74:42  \n[https://doi.org/10.1007/s12026-026-09762-6](https://doi.org/10.1007/s12026-026-09762-6)  \nREVIEW  \nInnovative biomaterial solutions for enhancing the efficacy of tumor immunotherapy  \nPengwei Zhu1,2  \nReceived: 4 November 2025 / Accepted: 27 February 2026 © The Author(s) 2026  \nAbstract  \nCancer remains a significant global health issue, exacerbated by population growth and aging. Immunotherapy has emerged as a promising treatment by leveraging the immune system to eliminate tumors. However, challenges such as inadequate immune activation, poor targeting, and side effects persist. Recent advancements in biomaterials, including liposomes, nanoparticles, micelles, and hydrogels, offer innovative solutions to these limitations. These engineered materials enhance the delivery and efficacy of immunotherapeutic agents, improve pharmacokinetics, enable controlled release, facilitate immune cell interactions, and reduce off-target toxicity. This review discusses the synergy between biomaterials and tumor immunotherapy, exploring current technologies, mechanisms, and future directions for personalized cancer treatments. Ongoing research in this interdisciplinary domain aims to develop next-generation immunotherapies with improved precision and therapeutic outcomes.  \n􀀍 Pengwei Zhu [pengwei_zhu@163.com](pengwei_zhu@163.com)  \n1 Bank of Beijing Post-Doctoral Research Station, Bank of Beijing, Beijing 100033, PR China  \n2 School of Public Health, University of Texas Health Science Center at Houston, Houston, TX 77030, USA  \n1 3  \nGraphical Abstract  \nKeywords Tumor immunotherapy · Biomaterials · Nanoparticle delivery · Tumor microenvironment · Controlled drug release  \nIntroduction  \nThe growing size and aging of the adult population have led to a rise in cancer cases and related deaths, making tumorsa significant global health concern. Researchers are actively seeking effective tumor treatments, which currently include surgery, radiotherapy, immunotherapy, chemotherapy, and targeted therapies. These various approaches have achieved some success in combating tumor cells. While surgery remains the primary method for treating solid tumors, chemotherapy and radiotherapy are more suitable for addressing dispersed tumor cells. Immunotherapy works by empowering the body’s immune defenses to identify and eliminate cancer cells [1] . Recently, advancements in antibody therapies and biotechnologies have emerged, with significant overlap among fields such as oncology, immunology, and molecular biology. Investigations into tumor immune evasion mechanisms and the tumor microenvironment (TME) have also expanded, leading to improved strategies for tumor immunotherapy [1] . This treatment represents a modern approach that stands apart from conventional options like surgery and chemotherapy. It offers several advantages,  \nincluding minimized damage to healthy organs, milder side effects, a lower likelihood of drug resistance, improved targeting of residual tumor cells, prolonged therapeutic effects, and a reduced chance of recurrence [2] .  \nDespite its promising benefits, immunotherapy still faces several challenges, including limited precision, weak immune activation in some patients, inefficient delivery of therapy, and unintended adverse effects [3] . To address these challenges, researchers are increasingly investigating biomaterials as a way to improve delivery systems andrefine the overall effectiveness of treatment. Biomaterials can extend circulation time, optimize pharmacokinetics, enable targeted delivery, improve cellular uptake and presentation, and regulate release profiles more effectively than conventional immunotherapeutic agents [4–6] . This review explores the various forms of tumor immunotherapy and their underlying mechanisms, with a particular focus on how biomaterials are advancing this field. It will detail the preparation and processing techniques of these materials, their modes of action, re","cbCaipa7VswzHP0B","https://ap.wps.com/l/cbCaipa7VswzHP0B","pdf",1896798,23,"English","# Introduction\n## Types of tumor immunotherapy\n### Cytokines","[{\"question\":\"What limitations currently hinder effective tumor immunotherapy?\",\"answer\":\"Key challenges include inadequate immune activation, poor targeting, inefficient delivery, limited precision, and unintended adverse effects in some patients.\"},{\"question\":\"How do biomaterials improve immunotherapy outcomes?\",\"answer\":\"Engineered biomaterials enhance delivery and efficacy of immunotherapeutic agents, improve pharmacokinetics, enable controlled release, facilitate immune-cell interactions, and reduce off-target toxicity.\"},{\"question\":\"Which cytokines are highlighted as early agents for cancer immunotherapy?\",\"answer\":\"The review points to interleukin-2 (IL-2) and interferon-alpha (IFN-α), both approved by the FDA for various cancer treatments, with noted limitations related to side effects or effectiveness.\"}]","Innovative biomaterial solutions for enhancing the efficacy of tumor immunotherapy | PDF",1790137760,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf6afb0c6305a1949d64e1ec0b12f1ac.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87105508c31833d391d319a59a8aea99.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/79d7dee9002192da2cfec65b9253636a.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ef308ebecc7fc81bb7664a8080f174f.webp",980,1301]